While it seems that sponsors of clinical trials usually end up with results that clearly favor their medicine, there are rare exceptions. Merck and Schering-Plough proved that with their disappointing ENHANCE Trial which many have heard about through the media. Vytorin is a combination pill for high cholesterol and contains Merck's Zocor, which is now generic, and Schering's Zetia, which works differently than Zocor -- one of many statin drugs.
If I were to rate the corruptive tactics performed by big pharmaceutical companies, the intentional corruption of implementing fabricated and unreliable results of clinical trials would be at the top of the list. Pharmaceutical companies manipulate the trials they sponsor because of their power to control others involved in the process largely absent of regulation. This is a matter of requiring authenticity and, more importantly, assuring the safety of the public health.
Researchers are constantly trying to find new drugs or forms of therapy that can be used to treat cancer. Quite often when a possible treatment is discovered, being allowed to test a drug or other experimental cancer treatment at a clinical level is difficult. For example, after an anti-carcinogenic drug has been thoroughly tested at the experimental level it is necessary to test it in humans to analyze factors such as the drugâ€™s anti-tumor activity, its ability to interact with a specific target, and to discover which patients are more likely to benefit from the drug. These types of early clinical trials are the key in the successful implementation of effective anti-tumor drugs and therapies.
Here, I present just two of the many possible "unknowns" about the medications that are prescribed by health care providers: 1. The FDA requires two studies to show that a medication that is awaiting approval from the FDA is superior to a placebo -- not exactly the best measurement of efficacy or the best reassurance that a patient is receiving the best medicinal treatment to restore their health. Equally surprising is that a pharmaceutical company that is attempting to approve such a medication has no limit as to the number of studies it can conduct to produce these two studies required.
- The Broken Mirror
- Surprising Role of Prions in Neurodegenerative Diseases